Rocket Pharmaceuticals is ready for liftoff in the rare disease space

With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.

By Taren Grom • Feb. 10, 2023

Bayer, Astellas switch CEOs amid major inflection points

Bayer’s Bill Anderson and Astellas’ Naoki Okamura will be charged with setting the companies on growth trajectories for 2023.

By Karissa Waddick • Feb. 9, 2023

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Woman of the Week: KaliVir Immunotherapeutics’ Helena Chaye

The triple threat CEO — scientist, lawyer and biotech pro — thinks she’s discovered a key to curing a wide range of cancers.

By Taren Grom • Feb. 8, 2023

The unique playbook of Biohaven’s CEO

Vlad Coric’s offbeat business strategy paid off once with a Pfizer buyout. Can he do it again?

By Meagan Parrish • Feb. 8, 2023

Leaps in vax tech — researchers find new ways to tackle old problems like fungal infections and cancer

A growing number of fungal infections has caused a stir in the research community, and new vaccines could be the answer down the road.

By Michael Gibney • Feb. 7, 2023

Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.

By Kelly Bilodeau • Feb. 6, 2023

Astria Therapeutics’ edge in an ultra-rare disease

With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

By Taren Grom • Feb. 1, 2023

Vaxxinity eyes global COVID-19 vaccine market with ‘next-gen’ booster

The biotech aims to complete rolling submissions with regulators in the U.K. and Australia in the first half of 2023.

By Alexandra Pecci • Jan. 31, 2023

This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic

With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.

By Michael Gibney • Jan. 31, 2023

A biotech CEO’s favorite ‘F’ word

At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.

By Taren Grom • Jan. 26, 2023

With Twitter in flux, pharma is turning to alternative social spaces

Elon Musk’s takeover of Twitter has upended the ways pharma companies communicate with doctors online. Now new social strategies are emerging.

By Karissa Waddick • Jan. 26, 2023

Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

By Meagan Parrish • Jan. 26, 2023

Woman of the Week: Dr. Lauren Lazar

As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

By Taren Grom • Jan. 25, 2023

Report reveals murky picture of clinical trial diversity gains

Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.

By Alexandra Pecci • Jan. 24, 2023

Drug price negotiations: 5 key dates to watch

As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.

By Kelly Bilodeau • Jan. 23, 2023

FDA’s 2022 drug approvals fall short of recent norms

The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.

By Alexandra Pecci • Jan. 19, 2023

After ‘limping along,’ Novavax sees a path forward

With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.

By Meagan Parrish • Jan. 18, 2023

A Moderna tie-up ushers in new era for CytomX

The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

By Michael Gibney • Jan. 18, 2023

Woman of the Week: Genetika+’s Talia Cohen Solal

The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

By Taren Grom • Jan. 18, 2023

The M&A hunt is on — here are the prime targets

Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.

By Kelly Bilodeau • Jan. 17, 2023

Focusing on smaller biotechs to have a big impact on society

Marcus Delatte discusses how and why he focuses his expertise on counseling smaller companies and mentoring the next generation of technical experts.

Jan. 17, 2023

How biotechs can weather the market storm

Execs at JPM sound off on moves companies can make to survive the challenging market conditions.

By Meagan Parrish • Jan. 13, 2023

Space — the next frontier in drug development

Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

By Kelly Bilodeau • Jan. 12, 2023

Biopharma M&A may get the push it needs in 2023, but with a face lift

A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

By Michael Gibney • Jan. 12, 2023

Woman of the Week: Form Bio’s Claire Aldridge

The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

By Taren Grom • Jan. 11, 2023